drugset / Trial / NCT00675844
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
Phase 2
Completed
7 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Extension study for participants currently participating in Protocols ACH443-015 and ACH443-018.
Timeline
- Start
- 2008-05
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elvucitabine | Small molecule | 10 mg | — |